ARE PROBIOTICS AND PREBIOTICS EFFECTIVE ADJUNCTIVE THERAPIES IN PARKINSON’S DISEASE?
Özet
Parkinson's disease (PD) is a progressive neurodegenerative condition, pathologically distinguished by the formation of intraneuronal composed of α-synuclein aggregates, which contribute to disease pathology and the development of both motor and non-motor clinical features. Regarding those diagnosed with PD, α-synuclein aggregation, enhanced intestinal permeability, bacterial translocation, and increased oxidative stress levels have been observed. PD associated with gut dysbiosis may be managed through dietary interventions, particularly with the use of probiotic and prebiotic supplementation. Therapeutic interventions such as probiotics can positively modulate the gut environment and, through their antioxidant properties, help limit excessive free radical production, thereby potentially slowing disease progression and reducing disease risk. Although several studies have investigated probiotic supplementation, research on prebiotics and synbiotics remains very limited.Recent findings have demonstrated that probiotic enrichment exerts promising beneficial effects in various human and animal models of disease and yields positive outcomes in improving disease symptoms. Studies suggest that probiotics may be particularly effective in alleviating Parkinson’s disease–related gastrointestinal dysfunctions and may also have potential value in improving motor symptoms, possibly through reducing inflammatory responses and fortifying neuronal function along the gut-brain axis. However, despite the fact that high-quality studies generally report improvements in disease symptoms, current evidence remains insufficient to support the routine use of prebiotics and probiotics in clinical practice for patients with PD. Further larger sample sizes, and well-designed randomized controlled trials are required. This section will comprehensively address the gut microbiota changes associated with PD, the potential mechanisms of action of prebiotics, probiotics, and synbiotics, and the current clinical evidence supporting the use of these approaches.
Anahtar Kelimeler: Parkinson disease, probiotic, prebiotic, synbiotic, microbiota
Konu Alanı: Biyoloji -> Biyoloji (diğer) -> Beslenme
Aponte, M., Murru, N., & Shoukat, M. (2020). Therapeutic, prophylactic, and functional use of probiotics: a current perspective. Frontiers in Microbiology, 11, 562048. https://doi.org/https://doi.org/10.3389/fmicb.2020.562048
Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: a review. Jama, 323(6), 548-560. https://doi.org/https://10.1001/jama.2019.22360
Atak, E. S., Yıldız, D., Kocatürk, R. R., Temizyürek, A., Özcan, Ö. Ö., Ergüzel, T. T., Karahan, M., & Tarhan, N. (2024). Therapeutic targets of probiotics in Parkinson disease: a systematic review of randomized controlled trials. Basic and Clinical Neuroscience, 15(2), 165. https://doi.org/https://10.32598/bcn.2022.3665.1
Ayesiga, I., Iqbal, S., Kyejjusa, Y., Okoboi, J., Omara, T., Adelina, T., Deogratias, D., Anyole, A. A., Kagimu, B. B., & Odongo, D. (2024). Key regulatory aspects of prebiotics, probiotics, and synbiotics in the management of metabolic disorders. In Synbiotics in Metabolic Disorders (pp. 214-244). CRC Press.
Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010). The genetics of Parkinson disease. Journal of geriatric psychiatry and neurology, 23(4), 228-242. https://doi.org/https://doi.org/10.1177/0891988710383572
Borzabadi, S., Oryan, S., Eidi, A., & Asemi, Z. (2018). The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: a randomized, double-blind, placebocontrolled trial. Archives of Iranian medicine, 21(7), 289-295.
Boyle, R. J., Robins-Browne, R. M., & Tang, M. L. (2006). Probiotic use in clinical practice: what are the risks? The American journal of clinical nutrition, 83(6), 1256-1264. https://doi.org/https://doi.org/10.1093/ajcn/83.6.1256
Cabanillas-Lazo, M., Pascual-Guevara, M., Chavez-Ecos, F. A., Alva-Diaz, C., Velasquez-Rimachi, V., Mori, N., & Micheli, F. (2026). Probiotic, Prebiotic, or Synbiotic Supplementation in Parkinson’s Disease: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. Gerontology, 126-141. https://doi.org/https://doi.org/10.1159/000547665
Cassani, E., Privitera, G., Pezzoli, G., Pusani, C., Madio, C., Iorio, L., & Barichella, M. (2011). Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva gastroenterologica e dietologica, 57(2), 117-121.
Corti, O., Lesage, S., & Brice, A. (2011). What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiological reviews. https://doi.org/https://doi.org/10.1152/physrev.00022.2010
Das, S., Fletcher, C. J., & Wu, Y. (2026). The Role of Different Dietary Fibers in Modulating Human Gut Microbiota. Nutraceuticals, 6(1), 18. https://doi.org/https://doi.org/10.3390/nutraceuticals6010018
Das, T. K., Pradhan, S., Chakrabarti, S., Mondal, K. C., & Ghosh, K. (2022). Current status of probiotic and related health benefits. Applied Food Research, 2(2), 100185. https://doi.org/https://doi.org/10.1016/j.afres.2022.100185
Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S. J., Berenjian, A., & Ghasemi, Y. (2019). Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods, 8(3), 92. https://doi.org/https://doi.org/10.3390/foods8030092
De Paula, J. A., Carmuega, E., & Weill, R. (2008). Effect of the ingestion of a symbiotic yogurt on the bowel habits of women with functional constipation. Acta Gastroenterologica Latinoamericana, 38(1), 16-25.
Delzenne, N. M. (2003). Oligosaccharides: state of the art. Proceedings of the Nutrition Society, 62(1), 177-182.
Dos Santos, J. C. C., Lima, M. P. P., de Castro Brito, G. A., & de Barros Viana, G. S. (2023). Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis. Ageing research reviews, 84, 101812. https://doi.org/https://doi.org/10.1016/j.arr.2022.101812
Du, Y., Wang, L., Cui, Y., Xu, X., Zhang, M., Li, Y., Gao, T., Gao, D., Sheng, Z., & Wang, S. (2025). Effect of probiotics supplementation on REM sleep behavior disorder and motor symptoms in Parkinson's disease: a pilot study. CNS Neuroscience & Therapeutics, 31(7), e70541. https://doi.org/https://doi.org/10.1111/cns.70541
Gazerani, P. (2019). Probiotics for Parkinson’s disease. International journal of molecular sciences, 20(17), 4121. https://doi.org/https://doi.org/10.3390/ijms20174121
Georgescu, D., Ancusa, O. E., Georgescu, L. A., Ionita, I., & Reisz, D. (2016). Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope? Clinical interventions in aging, 1601-1608. https://doi.org/https://doi.org/10.2147/CIA.S106284
Ghalandari, N., Assarzadegan, F., Mahdavi, H., Jamshidi, E., & Esmaily, H. (2023). Evaluating the effectiveness of probiotics in relieving constipation in Parkinson’s disease: A systematic review and meta-analysis. Heliyon, 9(3). https://doi.org/https://10.1016/j.heliyon.2023.e14312
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., & Cani, P. D. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature reviews Gastroenterology & hepatology, 14(8), 491-502. https://doi.org/https://10.1038/nrgastro.2017.75
Gibson, G. R., & Roberfroid, M. B. (1995). Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. The Journal of nutrition, 125(6), 1401-1412. https://doi.org/https://doi.org/10.1093/jn/125.6.1401
Gibson, G. R., Scott, K. P., Rastall, R. A., Tuohy, K. M., Hotchkiss, A., Dubert-Ferrandon, A., Gareau, M., Murphy, E. F., Saulnier, D., & Loh, G. (2010). Dietary prebiotics: current status and new definition. Food Science & Technology Bulletin: Functional Foods, 7(1), 1-19. https://doi.org/https://10.1616/1476-2137.15880
Guo, M., Gao, H., Wang, Y., & Xiang, Y. (2025). Exploring the role of gut microbiota in Parkinson’s disease: insights from fecal microbiota transplantation. Frontiers in neuroscience, 19, 1574512. https://doi.org/https://doi.org/10.3389/fnins.2025.1574512
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024). Microbiome-based therapeutics for Parkinson's disease. Neurotherapeutics, 21(6), e00462. https://doi.org/https://doi.org/10.1016/j.neurot.2024.e00462
Hong, C.-T., Chen, J.-H., & Huang, T.-W. (2022). Probiotics treatment for Parkinson disease: a systematic review and meta-analysis of clinical trials. Aging (Albany NY), 14(17), 7014. https://doi.org/https://10.18632/aging.204266
Hor, J. W., Toh, T. S., Lim, S.-Y., & Tan, A. H. (2024). Advice to people with Parkinson’s in my clinic: probiotics and prebiotics. Journal of Parkinson’s Disease, 14(7), 1507-1518. https://doi.org/https://doi.org/10.3233/JPD-240172
Jandhyala, S. M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., & Reddy, D. N. (2015). Role of the normal gut microbiota. World journal of gastroenterology: WJG, 21(29), 8787. https://doi.org/https://10.3748/wjg.v21.i29.8787
Jankovic, J., & Tan, E. K. (2020). Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry, 91(8), 795-808. https://doi.org/https://10.1136/jnnp-2019-322338
Jin, X., Dong, W., Chang, K., Yan, Y., & Liu, X. (2024). Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis. Complementary therapies in medicine, 82, 103045. https://doi.org/https://doi.org/10.1016/j.ctim.2024.103045
Khalighi, A., Khalighi, M., Behdani, R., Jamali, J., Khosravi, A., Kouhestani, S., Radmanesh, H., Esmaeelzadeh, S., & Khalighi, N. (2014). Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)-A pilot study. Indian Journal of Medical Research, 140(5), 604-608.
Khan, M. S., Nasiripour, S., & Bopassa, J. C. (2025). Parkinson disease signaling pathways, molecular mechanisms, and potential therapeutic strategies: a comprehensive review. International journal of molecular sciences, 26(13), 6416. https://doi.org/https://doi.org/10.3390/ijms26136416
Klann, E. M., Dissanayake, U., Gurrala, A., Farrer, M., Shukla, A. W., Ramirez-Zamora, A., Mai, V., & Vedam-Mai, V. (2022). The gut–brain axis and its relation to Parkinson’s disease: a review. Frontiers in aging neuroscience, 13, 782082. https://doi.org/https://doi.org/10.3389/fnagi.2021.782082
Kovács, T., Mikó, E., Vida, A., Sebő, É., Toth, J., Csonka, T., Boratkó, A., Ujlaki, G., Lente, G., & Kovács, P. (2019). Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Scientific Reports, 9(1), 1300. https://doi.org/https://doi.org/10.1038/s41598-018-37664-7
Kumar, D., Bishnoi, M., Kondepudi, K. K., & Sharma, S. S. (2025). Gut microbiota-based interventions for Parkinson’s disease: neuroprotective mechanisms and current perspective. Probiotics and Antimicrobial Proteins, 17(4), 2438-2460. https://doi.org/https://doi.org/10.1007/s12602-024-10433-x
Kutlu, T. (2011). Pre ve probiyotikler. Türk Pediatri Arşivi, 46(11), 59-64. https://doi.org/https://10.4274/tpa.46.36
Leta, V., Zinzalias, P., Batzu, L., Mandal, G., Staunton, J., Jernstedt, F., Rosqvist, K., Timpka, J., van Vliet, T., & Trivedi, D. (2025). Effects of a Four‐Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial. Movement Disorders, 40(12), 2710-2721. https://doi.org/https://doi.org/10.1002/mds.70047
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020). Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced mouse models of Parkinson’s disease. Brain, behavior, and immunity, 90, 26-46. https://doi.org/https://doi.org/10.1016/j.bbi.2020.07.036
Liu, W.-H., Chuang, H.-L., Huang, Y.-T., Wu, C.-C., Chou, G.-T., Wang, S., & Tsai, Y.-C. (2016). Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behavioural brain research, 298, 202-209. https://doi.org/https://doi.org/10.1016/j.bbr.2015.10.046
Liu, X., Du, Z. R., Wang, X., Sun, X. R., Zhao, Q., Zhao, F., Wong, W. T., Wong, K. H., & Dong, X.-L. (2022). Polymannuronic acid prebiotic plus Lacticaseibacillus rhamnosus GG probiotic as a novel synbiotic promoted their separate neuroprotection against Parkinson’s disease. Food Research International, 155, 111067. https://doi.org/https://doi.org/10.1016/j.foodres.2022.111067
Lu, C.-S., Chang, H.-C., Weng, Y.-H., Chen, C.-C., Kuo, Y.-S., & Tsai, Y.-C. (2021). The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson's disease: a pilot study. Frontiers in Nutrition, 8, 650053. https://doi.org/https://doi.org/10.3389/fnut.2021.650053
Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019). Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence. Frontiers in immunology, 10, 969. https://doi.org/https://doi.org/10.3389/fimmu.2019.00969
Mirzaei, H., Sedighi, S., Kouchaki, E., Barati, E., Dadgostar, E., Aschner, M., & Tamtaji, O. R. (2022). Probiotics and the treatment of Parkinson's disease: An update. Cellular and molecular neurobiology, 42(8), 2449-2457. https://doi.org/https://doi.org/10.1007/s10571-021-01128-w
Morshedi, M., Saghafi-Asl, M., & Hosseinifard, E.-S. (2020). The potential therapeutic effects of the gut microbiome manipulation by synbiotic containing-Lactobacillus plantarum on neuropsychological performance of diabetic rats. Journal of Translational Medicine, 18(1), 18. https://doi.org/https://doi.org/10.1186/s12967-019-02169-y
Musa, N. H., Mani, V., Lim, S. M., Vidyadaran, S., Majeed, A. B. A., & Ramasamy, K. (2017). Lactobacilli-fermented cow's milk attenuated lipopolysaccharide-induced neuroinflammation and memory impairment in vitro and in vivo. Journal of Dairy Research, 84(4), 488-495. https://doi.org/https://10.1017/S0022029917000620
Nurrahma, B. A., Tsao, S.-P., Wu, C.-H., Yeh, T.-H., Hsieh, P.-S., Panunggal, B., & Huang, H.-Y. (2021). Probiotic supplementation facilitates recovery of 6-OHDA-induced motor deficit via improving mitochondrial function and energy metabolism. Frontiers in aging neuroscience, 13, 668775. https://doi.org/https://doi.org/10.3389/fnagi.2021.668775
Ojukwu, E. A., Ojukwu, V. E., & Davis, J.-M. (2025). Evaluating Probiotic therapy as a Gut-Brain Microbiota and Neuroinflammation Modulator in Parkinson's disease: A Systematic Review. Junior Researchers, 3(2), 27-41. https://doi.org/https://doi.org/10.52340/jr.2025.03.02.06
Omotosho, A. O., Tajudeen, Y. A., Oladipo, H. J., Yusuff, S. I., AbdulKadir, M., Muili, A. O., Egbewande, O. M., Yusuf, R. O., Faniran, Z. O., & Afolabi, A. O. (2023). Parkinson's disease: Are gut microbes involved? Brain and behavior, 13(8), e3130. https://doi.org/https://doi.org/10.1002/brb3.3130
Panaitescu, P.-Ș., Răzniceanu, V., Mocrei-Rebrean, Ș.-M., Neculicioiu, V. S., Dragoș, H.-M., Costache, C., & Filip, G. A. (2024). The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson’s Disease Animal Models—A Systematic Review. Current Issues in Molecular Biology, 46(5), 3946-3974. https://doi.org/https://doi.org/10.3390/cimb46050244
Pandey, K., Naik, S., & Vakil, B. (2015). Probiotics, prebiotics and synbiotics-a review. Journal of Food Science and Technology, 52(12), 7577-7587. https://doi.org/https://10.1007/s13197-015-1921-1
Park, J. M., Lee, S. C., Ham, C., & Kim, Y. W. (2023). Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials. Gut Pathogens, 15(1), 9. https://doi.org/https://doi.org/10.1186/s13099-023-00536-1
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017). The gut-brain axis in Parkinson's disease: possibilities for food-based therapies. European journal of pharmacology, 817, 86-95. https://doi.org/http://dx.doi.org/10.1016/j.ejphar.2017.05.042
Rajkumar, H., Kumar, M., Das, N., Kumar, S. N., Challa, H. R., & Nagpal, R. (2015). Effect of probiotic Lactobacillus salivarius UBL S22 and prebiotic fructo-oligosaccharide on serum lipids, inflammatory markers, insulin sensitivity, and gut bacteria in healthy young volunteers: a randomized controlled single-blind pilot study. Journal of cardiovascular pharmacology and therapeutics, 20(3), 289-298. https://doi.org/https://doi.org/10.1177/1074248414555004
Ramesh, S., & Arachchige, A. S. P. M. (2023). Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS neuroscience, 10(3), 200. https://doi.org/https://10.3934/Neuroscience.2023017
Razafindralambo, H. L., Mathot, N., Fauconnier, M.-L., & Jijakli, M. H. (2026). A synbiotic approach to the formulation of innovative bioherbicides for weed control: a global perspective. Frontiers in Plant Science, 17, 1724814. https://doi.org/https://doi.org/10.3389/fpls.2026.1724814
Reid, G., Gadir, A. A., & Dhir, R. (2019). Probiotics: reiterating what they are and what they are not. Frontiers in Microbiology, 10, 424. https://doi.org/https://doi.org/10.3389/fmicb.2019.00424
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., Van Wezel, R. J., & Kraneveld, A. D. (2017). Exploring Braak’s hypothesis of Parkinson’s disease. Frontiers in neurology, 8, 37. https://doi.org/https://doi.org/10.3389/fneur.2017.00037
Salinas‐Velarde, I. D., Donaciano‐Domínguez, J. M., Oros‐Pantoja, R., Aguirre‐Garrido, J. F., González‐Cervantes, R. M., Munguía‐Cervantes, J. E., López, M. G., Bustos‐Martínez, J., & Soto‐Piña, A. E. (2025). Narrative Review: Gut Microbiota and Its Impact on α‐syn Function in Parkinson's Disease. MicrobiologyOpen, 14(6), e70173. https://doi.org/https://doi.org/10.1002/mbo3.70173
Simon, D. K., Tanner, C. M., & Brundin, P. (2020). Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clinics in geriatric medicine, 36(1), 1-12. https://doi.org/https://10.1016/j.cger.2019.08.002
Su, D., Cui, Y., He, C., Yin, P., Bai, R., Zhu, J., Lam, J. S., Zhang, J., Yan, R., & Zheng, X. (2025). Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. bmj, 388. https://doi.org/https://doi.org/10.1136/bmj-2024-080952
Sun, H., Zhao, F., Liu, Y., Ma, T., Jin, H., Quan, K., Leng, B., Zhao, J., Yuan, X., & Li, Z. (2022). Probiotics synergized with conventional regimen in managing Parkinson’s disease. npj Parkinson's Disease, 8(1), 62. https://doi.org/https://doi.org/10.1038/s41531-022-00327-6
Suresh, S. B., Malireddi, A., Abera, M., Noor, K., Ansar, M., Boddeti, S., & Nath, T. S. (2024). Gut microbiome and its role in Parkinson's disease. Cureus, 16(11). https://doi.org/https://10.7759/cureus.73150
Tamtaji, O. R., Taghizadeh, M., Kakhaki, R. D., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019). Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 38(3), 1031-1035. https://doi.org/https://doi.org/10.1016/j.clnu.2018.05.018
Tan, A. H., Lim, S.-Y., Chong, K. K., A Manap, M. A. A., Hor, J. W., Lim, J. L., Low, S. C., Chong, C. W., Mahadeva, S., & Lang, A. E. (2021). Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study. Neurology, 96(5), e772-e782. https://doi.org/https://doi.org/10.1212/WNL.0000000000010998
Tan, A. H., Mahadeva, S., Marras, C., Thalha, A. M., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., & Loke, M. F. (2015). Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism & related disorders, 21(3), 221-225. https://doi.org/https://doi.org/10.1016/j.parkreldis.2014.12.009
Tatar, B., & Öztürk, H. İ. (2022). The Concepts of Functional Component Beyond Probiotics: Postbiotics and Paraprobiotics. Turkish Journal of Agriculture-Food Science and Technology, 10(9), 1747-1755. https://doi.org/https://doi.org/10.24925/turjaf.v10i9.1747-1755.5439
Thangaleela, S., Sivamaruthi, B. S., Kesika, P., Bharathi, M., & Chaiyasut, C. (2022). Role of the gut–brain axis, gut microbial composition, diet, and probiotic intervention in Parkinson’s disease. Microorganisms, 10(8), 1544. https://doi.org/https://doi.org/10.3390/microorganisms10081544
Vázquez-Vélez, G. E., & Zoghbi, H. Y. (2021). Parkinson's disease genetics and pathophysiology. Annual review of neuroscience, 44(1), 87-108. https://doi.org/https://doi.org/10.1146/annurev-neuro-100720-
Visñuk, D. P., de Giori, G. S., LeBlanc, J. G., & de LeBlanc, A. d. M. (2020). Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model. Nutrition, 79, 110995. https://doi.org/https://doi.org/10.1016/j.nut.2020.110995
Wang, L., Cui, Y., Han, B., Du, Y., Salewala, K. S., Wang, S., Zhao, W., Zhang, H., Wang, S., & Xu, X. (2025). Gut microbiota and Parkinson’s disease. Chinese medical journal, 138(03), 289-297. https://doi.org/https://10.1097/CM9.0000000000003318
Xiang, S., Ji, J.-L., Li, S., Cao, X.-P., Xu, W., Tan, L., & Tan, C.-C. (2022). Efficacy and safety of probiotics for the treatment of Alzheimer's disease, mild cognitive impairment, and Parkinson's disease: a systematic review and meta-analysis. Frontiers in aging neuroscience, 14, 730036. https://doi.org/https://doi.org/10.3389/fnagi.2022.730036
Xie, C., & Prasad, A. A. (2020). Probiotics treatment improves hippocampal dependent cognition in a rodent model of Parkinson’s disease. Microorganisms, 8(11), 1661. https://doi.org/https://doi.org/10.3390/microorganisms8111661
Xie, L., Chen, D., Zhu, X., & Cheng, C. (2023). Efficacy and safety of probiotics in Parkinson’s constipation: a systematic review and meta-analysis. Frontiers in pharmacology, 13, 1007654. https://doi.org/https://doi.org/10.3389/fphar.2022.1007654
Yadav, M., Sehrawat, N., Sharma, A. K., Kumar, S., Singh, R., Kumar, A., & Kumar, A. (2024). Synbiotics as potent functional food: recent updates on therapeutic potential and mechanistic insight. Journal of Food Science and Technology, 61(1), 1-15. https://doi.org/https://doi.org/10.1007/s00253-021-11646-8
Yadav, M. K., Kumari, I., Singh, B., Sharma, K. K., & Tiwari, S. K. (2022). Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Applied microbiology and biotechnology, 106(2), 505-521. https://doi.org/https://doi.org/10.1007/s00253-021-11646-8
Yang, X., He, X., Xu, S., Zhang, Y., Mo, C., Lai, Y., Song, Y., Yan, Z., Ai, P., & Qian, Y. (2023). Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease. Food & Function, 14(15), 6828-6839. https://doi.org/https://10.1039/D3FO00728F
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023). Genetics and pathogenesis of Parkinson's syndrome. Annual Review of Pathology: Mechanisms of Disease, 18(1), 95-121. https://doi.org/https://doi.org/10.1146/annurev-pathmechdis-031521-034145
Yemula, N., Dietrich, C., Dostal, V., & Hornberger, M. (2021). Parkinson’s disease and the gut: symptoms, nutrition, and microbiota. Journal of Parkinson’s Disease, 11(4), 1491-1505. https://doi.org/https://doi.org/10.3233/JPD-212707
Yin, S., & Zhu, F. (2022). Probiotics for constipation in Parkinson’s: A systematic review and meta-analysis of randomized controlled trials. Frontiers in cellular and infection microbiology, 12, 1038928. https://doi.org/https://doi.org/10.3389/fcimb.2022.1038928
Youssef, M., Ahmed, H. Y., Zongo, A., Korin, A., Zhan, F., Hady, E., Umair, M., Shahid Riaz Rajoka, M., Xiong, Y., & Li, B. (2021). Probiotic supplements: their strategies in the therapeutic and prophylactic of human life-threatening diseases. International journal of molecular sciences, 22(20), 11290. https://doi.org/https://doi.org/10.3390/ijms222011290
Zhang, Y., Liu, S., Xu, K., Zhou, Y., Shen, Y., Liu, Z., Bai, Y., & Wang, S. (2024). Non-pharmacological therapies for treating non-motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis. Frontiers in aging neuroscience, 16, 1363115. https://doi.org/https://doi.org/10.3389/fnagi.2024.1363115
Zhou, L., Wong, K. Y., & Xie, H. (2025). Modulation of intestinal inflammation and protection of dopaminergic neurons in Parkinson’s disease mice through a probiotic formulation targeting NLRP3 inflammasome. Journal of Neuroimmune Pharmacology, 20(1), 9. https://doi.org/https://doi.org/10.1007/s11481-024-10163-5
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023). Role of dopamine in the pathophysiology of Parkinson’s disease. Translational neurodegeneration, 12(1), 44. https://doi.org/https://doi.org/10.1186/s40035-023-00378-6